Inhibitors that selectively target the formation of the NLRP3 inflammasome, preventing the cleavage of pro-caspase 1, and the downstream effectors (activation of IL-1β) are widely desired and currently in development for the treatment of cardiovascular diseases [64]. The gene discussed is IL1B; the disease is cardiovascular disorder.